Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia

David Rosow, Punam Parikh, Richard J. Vivero, Roy R Casiano, Donna Lundy

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objectives. To assess the effect on voice improvement and duration of breathiness based on initial dose of onabotulinum toxin A (BTX-A) in the management of adductor spasmodic dysphonia (SD) and to compare voice outcomes for initial bilaterally injected doses of 1.25 units (group A) vs 2.5 units (group B) of BTX-A. Study Design. Case series with chart review of patients with adductor SD treated at a tertiary care facility from 1990 to 2011. Setting. Academic subspecialty laryngology practice. Methods. Demographic data (age and sex), voice rating, duration of voice improvement, and breathiness were evaluated and compared between groups A and B using the Student t test and x2 analysis. Results. Of 478 patients identified, 305 (223 in group A, 82 in group B) patients met inclusion criteria. The average age was 56.2 years in group A and 57.4 years in group B (P = .5). The female to male ratio was 2.91 for group A vs 3.56 for group B (P = .61). Good voice outcomes (grade 3 or 4) were reported by 91% of group A patients vs 94% of group B (P = .75). The average duration of voice improvement was 99.7 days for group A and 108.3 days for group B (P = .54). The average duration of breathiness was 10.88 days for group A vs 15.42 days for group B (P = .02). Conclusion. Patients injected with 1.25 units bilaterally had a statistically significant shorter duration of breathiness without a statistically significant difference in clinical effectiveness or voice outcome. It is therefore recommended that a relatively low initial BTX-A dose be used with subsequent titration to achieve improved voice outcomes.

Original languageEnglish
Pages (from-to)1003-1006
Number of pages4
JournalOtolaryngology - Head and Neck Surgery (United States)
Volume148
Issue number6
DOIs
StatePublished - Jun 1 2013

Fingerprint

Dysphonia
Botulinum Toxins
Therapeutics
Otolaryngology
Tertiary Healthcare
Demography
Students

Keywords

  • Botox
  • Botulinum toxin
  • Dosing
  • Dystonia
  • Neurolaryngology
  • Spasmodic dysphonia
  • Voice

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Surgery
  • Medicine(all)

Cite this

Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia. / Rosow, David; Parikh, Punam; Vivero, Richard J.; Casiano, Roy R; Lundy, Donna.

In: Otolaryngology - Head and Neck Surgery (United States), Vol. 148, No. 6, 01.06.2013, p. 1003-1006.

Research output: Contribution to journalArticle

@article{f545152a388c4c4fa207f2c24992d7e6,
title = "Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia",
abstract = "Objectives. To assess the effect on voice improvement and duration of breathiness based on initial dose of onabotulinum toxin A (BTX-A) in the management of adductor spasmodic dysphonia (SD) and to compare voice outcomes for initial bilaterally injected doses of 1.25 units (group A) vs 2.5 units (group B) of BTX-A. Study Design. Case series with chart review of patients with adductor SD treated at a tertiary care facility from 1990 to 2011. Setting. Academic subspecialty laryngology practice. Methods. Demographic data (age and sex), voice rating, duration of voice improvement, and breathiness were evaluated and compared between groups A and B using the Student t test and x2 analysis. Results. Of 478 patients identified, 305 (223 in group A, 82 in group B) patients met inclusion criteria. The average age was 56.2 years in group A and 57.4 years in group B (P = .5). The female to male ratio was 2.91 for group A vs 3.56 for group B (P = .61). Good voice outcomes (grade 3 or 4) were reported by 91{\%} of group A patients vs 94{\%} of group B (P = .75). The average duration of voice improvement was 99.7 days for group A and 108.3 days for group B (P = .54). The average duration of breathiness was 10.88 days for group A vs 15.42 days for group B (P = .02). Conclusion. Patients injected with 1.25 units bilaterally had a statistically significant shorter duration of breathiness without a statistically significant difference in clinical effectiveness or voice outcome. It is therefore recommended that a relatively low initial BTX-A dose be used with subsequent titration to achieve improved voice outcomes.",
keywords = "Botox, Botulinum toxin, Dosing, Dystonia, Neurolaryngology, Spasmodic dysphonia, Voice",
author = "David Rosow and Punam Parikh and Vivero, {Richard J.} and Casiano, {Roy R} and Donna Lundy",
year = "2013",
month = "6",
day = "1",
doi = "10.1177/0194599813484685",
language = "English",
volume = "148",
pages = "1003--1006",
journal = "Otolaryngology - Head and Neck Surgery (United States)",
issn = "0194-5998",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia

AU - Rosow, David

AU - Parikh, Punam

AU - Vivero, Richard J.

AU - Casiano, Roy R

AU - Lundy, Donna

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Objectives. To assess the effect on voice improvement and duration of breathiness based on initial dose of onabotulinum toxin A (BTX-A) in the management of adductor spasmodic dysphonia (SD) and to compare voice outcomes for initial bilaterally injected doses of 1.25 units (group A) vs 2.5 units (group B) of BTX-A. Study Design. Case series with chart review of patients with adductor SD treated at a tertiary care facility from 1990 to 2011. Setting. Academic subspecialty laryngology practice. Methods. Demographic data (age and sex), voice rating, duration of voice improvement, and breathiness were evaluated and compared between groups A and B using the Student t test and x2 analysis. Results. Of 478 patients identified, 305 (223 in group A, 82 in group B) patients met inclusion criteria. The average age was 56.2 years in group A and 57.4 years in group B (P = .5). The female to male ratio was 2.91 for group A vs 3.56 for group B (P = .61). Good voice outcomes (grade 3 or 4) were reported by 91% of group A patients vs 94% of group B (P = .75). The average duration of voice improvement was 99.7 days for group A and 108.3 days for group B (P = .54). The average duration of breathiness was 10.88 days for group A vs 15.42 days for group B (P = .02). Conclusion. Patients injected with 1.25 units bilaterally had a statistically significant shorter duration of breathiness without a statistically significant difference in clinical effectiveness or voice outcome. It is therefore recommended that a relatively low initial BTX-A dose be used with subsequent titration to achieve improved voice outcomes.

AB - Objectives. To assess the effect on voice improvement and duration of breathiness based on initial dose of onabotulinum toxin A (BTX-A) in the management of adductor spasmodic dysphonia (SD) and to compare voice outcomes for initial bilaterally injected doses of 1.25 units (group A) vs 2.5 units (group B) of BTX-A. Study Design. Case series with chart review of patients with adductor SD treated at a tertiary care facility from 1990 to 2011. Setting. Academic subspecialty laryngology practice. Methods. Demographic data (age and sex), voice rating, duration of voice improvement, and breathiness were evaluated and compared between groups A and B using the Student t test and x2 analysis. Results. Of 478 patients identified, 305 (223 in group A, 82 in group B) patients met inclusion criteria. The average age was 56.2 years in group A and 57.4 years in group B (P = .5). The female to male ratio was 2.91 for group A vs 3.56 for group B (P = .61). Good voice outcomes (grade 3 or 4) were reported by 91% of group A patients vs 94% of group B (P = .75). The average duration of voice improvement was 99.7 days for group A and 108.3 days for group B (P = .54). The average duration of breathiness was 10.88 days for group A vs 15.42 days for group B (P = .02). Conclusion. Patients injected with 1.25 units bilaterally had a statistically significant shorter duration of breathiness without a statistically significant difference in clinical effectiveness or voice outcome. It is therefore recommended that a relatively low initial BTX-A dose be used with subsequent titration to achieve improved voice outcomes.

KW - Botox

KW - Botulinum toxin

KW - Dosing

KW - Dystonia

KW - Neurolaryngology

KW - Spasmodic dysphonia

KW - Voice

UR - http://www.scopus.com/inward/record.url?scp=84880483718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880483718&partnerID=8YFLogxK

U2 - 10.1177/0194599813484685

DO - 10.1177/0194599813484685

M3 - Article

C2 - 23535709

AN - SCOPUS:84880483718

VL - 148

SP - 1003

EP - 1006

JO - Otolaryngology - Head and Neck Surgery (United States)

JF - Otolaryngology - Head and Neck Surgery (United States)

SN - 0194-5998

IS - 6

ER -